16-Jun-2026
Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
Globe Newswire (Thu, 11-Jun 8:30 AM ET)
Zevra’s MIPLYFFA Patent Listing Extends Protection to 2041—What This Means for Long-Term Exclusivity
Market Chameleon (Mon, 8-Jun 5:26 AM ET)
Globe Newswire (Mon, 8-Jun 7:30 AM ET)
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 29-May 4:30 PM ET)
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
Globe Newswire (Tue, 12-May 7:30 AM ET)
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
Globe Newswire (Wed, 6-May 4:05 PM ET)
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call
Globe Newswire (Wed, 22-Apr 7:30 AM ET)
Globe Newswire (Fri, 20-Mar 4:30 PM ET)
Zevra’s 2025 Financials Signal Turnaround as MIPLYFFA Drives Rare Disease Momentum
Market Chameleon (Tue, 10-Mar 5:53 AM ET)
Market Chameleon (Tue, 10-Mar 3:06 AM ET)
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Zevra Therapeutics trades on the NASDAQ stock market under the symbol ZVRA.
As of June 16, 2026, ZVRA stock price climbed to $12.65 with 1,198,411 million shares trading.
ZVRA has a beta of 0.58, meaning it tends to be less sensitive to market movements. ZVRA has a correlation of 0.01 to the broad based SPY ETF.
ZVRA has a market cap of $747.80 million. This is considered a Small Cap stock.
Last quarter Zevra Therapeutics reported $36 million in Revenue and $.18 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.10.
In the last 3 years, ZVRA traded as high as $14.27 and as low as $3.89.
The top ETF exchange traded funds that ZVRA belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
ZVRA has outperformed the market in the last year with a price return of +38.6% while the SPY ETF gained +26.9%. ZVRA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +26.8% and +10.1%, respectively, while the SPY returned +13.6% and -1.1%, respectively.
ZVRA support price is $12.02 and resistance is $13.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZVRA shares will trade within this expected range on the day.
